New drug CAY001 enters first human safety trial
Knowledge-focused
Recruiting now
This early-stage study tests the safety of a new drug called CAY001 in 24 healthy adults aged 18-50. Participants receive a single dose of the drug or a placebo by IV, and researchers monitor them for 28 days for side effects and how the drug moves through the body. The goal is s…
Phase: PHASE1 • Sponsor: Cayuga Biotech, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC